Home » FDA Expands Approval of Bristol-Myers Squibb’s Empliciti
FDA Expands Approval of Bristol-Myers Squibb’s Empliciti
Bristol-Myers Squibb announced that the FDA has granted its multiple myeloma treatment Empliciti (elotuzumab) expanded approval.
The treatment is now approved for intravenous use as a combination therapy with pomalidomide and dexamethasone (EPd) for treating multiple myeloma in adult patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
EPd is the first triplet combination approved based on a randomized clinical trial using pomalidomide and dexamethasone as comparators.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May